Cognex Price Target Announced at $58.00/Share by Vertical Research
Cognex Analyst Ratings
Intuitive Surgical Analyst Ratings
Vertical Research Initiates Cognex at Buy With $58 Price Target
Truist Financial Sticks to Its Buy Rating for Intuitive Surgical (ISRG)
Barclays Adjusts Price Target on Intuitive Surgical to $510 From $490
Nvidia Price Target Raised to $140.00/Share From $120.00 by Piper Sandler
NVIDIA Analyst Ratings
Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)
Outperform Rating Reaffirmed for Intuitive Surgical on Strong Q2 2024 Performance and Da Vinci 5 Launch Success
BMO Capital Cuts Price Target on Dynatrace to $49 From $54, Maintains Outperform Rating
Dynatrace Analyst Ratings
Baird Maintains Outperform on Intuitive Surgical, Raises Price Target to $503
Piper Sandler Remains a Buy on Intuitive Surgical (ISRG)
Morgan Stanley Adjusts Price Target on Intuitive Surgical to $475 From $460, Maintains Equalweight Rating
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)
Strong Performance and Growth Prospects Underpin Buy Rating for Intuitive Surgical
Intuitive Surgical Analyst Ratings
Citi Sticks to Its Buy Rating for Dynatrace (DT)
Barclays Remains a Buy on Intuitive Surgical (ISRG)